HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 288/6/C1193    most recent 00499.2004v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Ginnan, R. Articles by Singer, H. A. Search for Related Content PubMed PubMed Citation Articles by Ginnan, R. Articles by Singer, H. A.

TRANSLATIONAL PHYSIOLOGY

PKC--dependent pathways contribute to PDGF-stimulated ERK1/2 activation in vascular smooth muscle

Center for Cardiovascular Sciences, Albany Medical College, Albany, New York

Submitted 12 October 2004 ; accepted in final form 18 January 2005

ABSTRACT

Platelet-derived growth factor (PDGF) is an important regulator of vascular smooth muscle (VSM) cell growth and migration and has been identified as a key mediator of neointima formation resulting from vascular injury. PDGF exerts its effects, in part, through activation of ERK1/2. Previously, we reported that PKC-, specifically compared with PKC-, mediated phorbol ester- and ATP-dependent activation of ERK1/2 in VSM cells. The purpose of this study was to determine whether PKC- was involved in PDGF-dependent activation of ERK1/2 in VSM cells. The addition of PDGF resulted in the activation, and Src family kinase-dependent tyrosine phosphorylation, of PKC-. Treatment with rottlerin (0.1–10 µM), a selective PKC- inhibitor, or adenoviral overexpression of kinase-negative PKC- significantly attenuated PDGF-induced activation of ERK1/2. The effects of the PKC- inhibitors decreased with increasing concentrations of activator PDGF. Interestingly, treatment with Gö6976 (0.1–3 µM), a selective inhibitor of cPKCs, or adenoviral overexpression of kinase-negative PKC- also inhibited PDGF-stimulated ERK1/2. Furthermore, inhibition of cPKC activity with Gö6976 or overexpression of kinase-negative PKC- attenuated PKC- activation and tyrosine phosphorylation in response to PDGF. These studies indicate involvement of both PKC- and PKC- isozymes in PDGF-stimulated signaling in VSM and suggest an unexpected role for PKC- in the regulation of PKC- activity.

phospholipase C-; protein kinase C-; protein kinase C-

This article has been cited by other articles:

				D. Yamanouchi, K. Kato, E. J. Ryer, F. Zhang, and B. Liu Protein kinase C delta mediates arterial injury responses through regulation of vascular smooth muscle cell apoptosis Cardiovasc Res, October 31, 2009; (2009) cvp328v2. [Abstract] [Full Text] [PDF]

				I. T. Makagiansar, S. Williams, T. Mustelin, and W. B. Stallcup Differential phosphorylation of NG2 proteoglycan by ERK and PKC{alpha} helps balance cell proliferation and migration J. Cell Biol., October 3, 2007; 178(1): 155 - 165. [Abstract] [Full Text] [PDF]

				I. Papparella, G. Ceolotto, L. Berto, M. Cavalli, S. Bova, G. Cargnelli, E. Ruga, O. Milanesi, L. Franco, M. Mazzoni, et al. Vitamin C prevents zidovudine-induced NAD(P)H oxidase activation and hypertension in the rat Cardiovasc Res, January 15, 2007; 73(2): 432 - 438. [Abstract] [Full Text] [PDF]

				L. E. Kilpatrick, S. Sun, D. Mackie, F. Baik, H. Li, and H. M. Korchak Regulation of TNF mediated antiapoptotic signaling in human neutrophils: role of {delta}-PKC and ERK1/2 J. Leukoc. Biol., December 1, 2006; 80(6): 1512 - 1521. [Abstract] [Full Text] [PDF]

				R. Ginnan, B. J. Guikema, H. A. Singer, and D. Jourd'heuil PKC-{delta} mediates activation of ERK1/2 and induction of iNOS by IL-1beta in vascular smooth muscle cells Am J Physiol Cell Physiol, June 1, 2006; 290(6): C1583 - C1591. [Abstract] [Full Text] [PDF]